drugset / Trial / NCT00367913
Clarithromycin v Ciprofloxacin Added to Rifampicin + Ethambutol, for Opportunist Mycobacterial Pulmonary Disease
RandomizedFactorialOpen-labelTreatment
Summary
To date key drugs in the treatment of MAIS, M.malmoense and M.xenopi (Opportunist Mycobacteria have been rifampicin and ethambutol. Clarithromycin and Ciprofloxacin are active in vitro against these species of mycobacteria. The primary aim of this study was to compare these to agents as supplements to rifampicin and ethambutol. A secondary aim was to assess the vale of immunotherapy with M.vaccae.
Timeline
- Start
- 1995-03
- Primary completion
- —
- Completion
- 2004-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ciprofloxacin | Small molecule | — | — |
| Subject | Clarithromycin | Small molecule | — | — |
| Subject | M.vaccae | Vaccine | — | — |
| Background | Ethambutol | Small molecule | — | — |
| Background | Rifampin | Small molecule | — | — |